Literature DB >> 15616503

Photorefractive keratectomy followed by strabismus surgery for the treatment of partly accommodative esotropia.

Paolo Nucci1, Massimiliano Serafino, Amy K Hutchinson.   

Abstract

PURPOSE: To evaluate photorefractive keratectomy (PRK) followed by bilateral medial rectus muscle recessions (BMR) to treat adults with partly accommodative esotropia.
METHODS: We reviewed medical records of 10 consecutive patients with partly accommodative esotropia who underwent PRK to correct hyperopia followed 6 months later by BMR to treat the accommodative and nonaccommodative components of their esotropia, respectively. Visual acuity, spherical equivalent of refractive error, alignment, and sensory data were collected and analyzed.
RESULTS: Twenty eyes of 10 patients were treated and followed for 1 year. PRK was successful in treating the hyperopia (mean post-PRK spherical equivalent was 0.14 D (SD = 0.22)) and the accommodative portion of the esotropia (the mean percentage of the distance accommodative component eliminated by PRK was 101.67% and the mean percentage of the near accommodative component eliminated by PRK was 115%). However, subsequent BMR using standard surgical tables based on the distance deviation to treat the post-PRK residual (nonaccommodative) esotropia resulted in uniform undercorrection.
CONCLUSION: PRK may be useful to treat the accommodative portion of partly accommodative esotropia. Bilateral medial rectus muscle recession can be used to treat the residual, nonaccommodative component; however, it may be necessary to base the surgical dosage on the near deviation.

Entities:  

Mesh:

Year:  2004        PMID: 15616503     DOI: 10.1016/j.jaapos.2004.09.003

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  1 in total

1.  Photorefractive keratectomy for the treatment of purely refractive accommodative esotropia: 6 years' experience.

Authors:  A K Hutchinson; M Serafino; P Nucci
Journal:  Br J Ophthalmol       Date:  2010-02       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.